CDT Equity Inc CDT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
-
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
-
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
-
CDT Equity Inc. Announces Reverse Stock Split
-
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
-
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
-
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
-
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
Trading Information
- Previous Close Price
- $0.08
- Day Range
- $0.07–0.08
- 52-Week Range
- $0.07–18,628.13
- Bid/Ask
- $0.07 / $0.07
- Shares Outstanding
- 9.32M
- Market Cap
- $59,346.06
- Volume/Avg
- 176,246 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 4
- Website
- https://www.cdtequity.com
Valuation
|
Metric
|
CDT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CDT
|
|---|---|
Quick Ratio | 0.04 |
Current Ratio | 0.13 |
Interest Coverage | −243.49 |
Quick Ratio
CDT
Profitability
|
Metric
|
CDT
|
|---|---|
Return on Assets (Normalized) | −60.64% |
Return on Equity (Normalized) | −80.01% |
Return on Invested Capital (Normalized) | −77.20% |
Return on Assets
CDT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|y@j>D$ | LOCK|q#s$ | $137B | |||
| Moderna Inc
MRNA
| LOCK|$z!<>f | LOCK|<F^ | $89B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|ZZyV?w | LOCK|n?%% | $84B | |||
| argenx SE ADR
ARGX
| LOCK|m!>?&fj | LOCK|b@? | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Fy^^&>m | LOCK|KF | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|ny#XpbBP | LOCK|@N?q | $29B | |||
| Incyte Corp
INCY
| LOCK|>@n^@DW | LOCK|xT | $24B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|m&h#&DS | LOCK|z^#N$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|xmz?nt^ | LOCK|S> | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Bk#>?kw | LOCK|lR# | $14B |
United States